Interestingly, cases from the GHEDI series with high c-Rel DNA-binding and c-Rel signature more frequently exhibited the genetic events previously ascribed to GCB-DLBCLs and follicular lymphomas (FL) (1), including BCL2 translocation, MEF2B and EZH2 gain of function mutations as well as loss of function of the tumor suppressors CREBBP, and TNFRSF14. MEF2B may control BCL6 which in turn regulates LMO2 and MYBL1 (41), the latter being up-regulated in both GCB and c-Rel signatures. This evidence concerns the gene CREBBP and follicular lymphoma.